These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 11970766)

  • 21. Tumour-targeted chemotherapy with immunoconjugates of calicheamicin.
    Damle NK
    Expert Opin Biol Ther; 2004 Sep; 4(9):1445-52. PubMed ID: 15335312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.
    Arceci RJ; Sande J; Lange B; Shannon K; Franklin J; Hutchinson R; Vik TA; Flowers D; Aplenc R; Berger MS; Sherman ML; Smith FO; Bernstein I; Sievers EL
    Blood; 2005 Aug; 106(4):1183-8. PubMed ID: 15886328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse.
    Dowell JA; Korth-Bradley J; Liu H; King SP; Berger MS
    J Clin Pharmacol; 2001 Nov; 41(11):1206-14. PubMed ID: 11697753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
    Stadtmauer EA
    Curr Oncol Rep; 2002 Sep; 4(5):375-80. PubMed ID: 12162910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
    Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leukemic gingival infiltrate as an indicator of chemotherapeutic failure following monoclonal antibody therapy: a case report.
    Sollecito TP; Draznin J; Parisi E; Duffy K; Stadtmauer EA; Luger SM; Schuster SJ; Tsai D; Porter DL
    Spec Care Dentist; 2003; 23(3):108-10. PubMed ID: 14650559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Antibody directed therapy for leukemia].
    Takeshita A; Naito K; Ohno R
    Nihon Rinsho; 2002 Mar; 60(3):517-24. PubMed ID: 11904967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of gemtuzumab ozogamicin in acute leukaemia therapy.
    Tsimberidou AM; Giles FJ; Estey E; O'Brien S; Keating MJ; Kantarjian HM
    Br J Haematol; 2006 Feb; 132(4):398-409. PubMed ID: 16412015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New developments in antibody therapy for acute myeloid leukemia.
    Tomblyn MR; Tallman MS
    Semin Oncol; 2003 Aug; 30(4):502-8. PubMed ID: 12939719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts.
    Walter RB; Boyle KM; Appelbaum FR; Bernstein ID; Pagel JM
    Blood; 2008 May; 111(9):4813-6. PubMed ID: 18326813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
    Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
    Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity.
    Walter RB; Raden BW; Kamikura DM; Cooper JA; Bernstein ID
    Blood; 2005 Feb; 105(3):1295-302. PubMed ID: 15454492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody therapy for acute myeloid leukemia.
    Mulford D
    Semin Hematol; 2008 Apr; 45(2):104-9. PubMed ID: 18381105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gemtuzumab ozogamicin in acute myeloid leukemia.
    Godwin CD; Gale RP; Walter RB
    Leukemia; 2017 Sep; 31(9):1855-1868. PubMed ID: 28607471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What happened to anti-CD33 therapy for acute myeloid leukemia?
    Jurcic JG
    Curr Hematol Malig Rep; 2012 Mar; 7(1):65-73. PubMed ID: 22109628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.
    Sievers EL; Larson RA; Stadtmauer EA; Estey E; Löwenberg B; Dombret H; Karanes C; Theobald M; Bennett JM; Sherman ML; Berger MS; Eten CB; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR;
    J Clin Oncol; 2001 Jul; 19(13):3244-54. PubMed ID: 11432892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
    Balaian L; Ball ED
    Leukemia; 2006 Dec; 20(12):2093-101. PubMed ID: 17051243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemtuzumab ozogamicin.
    McGavin JK; Spencer CM
    Drugs; 2001; 61(9):1317-22; discussion 1323-4. PubMed ID: 11511025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells.
    ten Cate B; Samplonius DF; Bijma T; de Leij LF; Helfrich W; Bremer E
    Leukemia; 2007 Feb; 21(2):248-52. PubMed ID: 17122863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.
    Jedema I; Barge RM; van der Velden VH; Nijmeijer BA; van Dongen JJ; Willemze R; Falkenburg JH
    Leukemia; 2004 Feb; 18(2):316-25. PubMed ID: 14614514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.